Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity, Inc. granted Chief Executive Officer Jeffrey Tangney a stock option covering 2,480,000 shares of Class A Common Stock at an exercise price of $28.02 per share, expiring July 22, 2036.
The option vests in four equal annual installments beginning July 22, 2027, only if the share price equals or exceeds $28.02 for any 60 consecutive trading days between July 22, 2026 and July 22, 2030 and he remains in continuous service.
Doximity, Inc. President Steven L. Zatz received a grant of stock options for 150,000 shares of Class A Common Stock on July 22, 2026, with an exercise price of $20.49 per share. The options vest in three equal annual installments starting July 22, 2027, subject to his continuous service, and expire on July 22, 2036; all 150,000 options are held as direct beneficial ownership.
Doximity Chief Accounting Officer Siddharth Sitaram reported selling 1,732 shares of Class A Common Stock on July 15, 2026 at $22.02 per share. These shares were sold in a sell-to-cover transaction to satisfy tax withholding obligations related to an option exercise and occurred automatically pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026, leaving him with 93,774 Class A shares held directly.
On the same date he exercised stock options for 4,800 shares at an exercise price of $4.1200 per share, acquiring Class B shares that were converted one-for-one into Class A Common Stock. After this exercise, 64,000 option shares remain outstanding, with the option expiring on December 21, 2030.
DOCS reporting person Siddharth filed a Form 144 notice for a proposed sale of up to 1,732 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, expected on July 15, 2026, following a stock option exercise for cash.
The notice also lists prior sales in the past three months of 2,444 shares for 49,882.04 on June 8, 2026 and 2,309 shares for 59,502.93 on May 11, 2026.
Doximity, Inc. will hold its fiscal 2026 annual meeting on August 27, 2026 at 9:00 a.m. Pacific Time, conducted as an audio-only virtual event for stockholders of record as of July 2, 2026. Holders of Class A and high-vote Class B common stock will vote together as a single class.
Stockholders are asked to elect two Class II directors, Kevin Spain and Timothy Cabral, to terms ending in 2029, ratify Deloitte & Touche LLP as independent auditor for the year ending March 31, 2027, and approve an advisory Say‑on‑Pay resolution on 2026 executive compensation. The board recommends voting “FOR” all proposals.
The proxy describes Doximity’s classified, majority‑independent board, committee structure, director and executive biographies, and governance policies including an insider-trading and hedging ban, a Dodd‑Frank–compliant clawback policy, and cybersecurity and HIPAA-focused controls. It also details non‑employee director pay, with cash retainers and RSU grants, and reports $3,047,251 in total fees paid to Deloitte in fiscal 2026.
Doximity, Inc. director Benjamin M. Regina reported an equity award of 9,750 restricted stock units (RSUs) of Class A Common Stock granted on November 15, 2025 under the 2021 Stock Option and Incentive Plan. The award reflects a correction from an original 31,064-RSU grant, of which 21,314 RSUs were deemed not validly granted and void ab initio. The 9,750 RSUs vest in four installments through November 15, 2026, and each RSU converts into one share upon vesting, leaving Regina with 29,589 shares held directly after the award.
Benjamin Regina M. reported acquisition or exercise transactions in this Form 4 filing.
Doximity, Inc. reported that director Benjamin Regina M. received a grant of 21,314 restricted stock units of Class A common stock on July 13, 2026 under the 2021 Stock Option and Incentive Plan at $0.0000 per share. 2,676 RSUs vest on November 15, 2026, with the remainder vesting in six equal quarterly installments through May 15, 2028, subject to continued service. Following the award, his direct Class A holdings total 50,903 shares.
Doximity, Inc. filed an initial ownership report for Chief Financial Officer Matthew Sonefeldt, showing 501,549 shares of Class A Common Stock. This total includes 499,722 restricted stock units (RSUs) granted on May 15, 2026, which vest in equal quarterly installments over 36 months beginning on August 15, 2026, contingent on continued service.
ZATZ STEVEN L reported acquisition or exercise transactions in this Form 4 filing.
Doximity, Inc. President Steven L. Zatz reported receiving an equity award of 55,524 shares of Class A Common Stock in the form of restricted stock units. These RSUs were granted on May 15, 2026 and will vest in equal quarterly installments over 12 months beginning on August 15, 2026, contingent on his continued service. Each RSU represents a right to receive one share of Class A Common Stock, and following this grant he holds 56,346 shares directly.